Currencies36101
Market Cap$ 3.32T-0.68%
24h Spot Volume$ 63.41B-7.38%
DominanceBTC55.55%+0.14%ETH11.41%+0.58%
ETH Gas0.05 Gwei
/

Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR


by Wajeeh Khan
for Invezz
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR

Share:

martin shkreli qcls stock long idea bad call capr

Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”.

According to him, the photonic computing firm could be trading at $100 per share, and that too in the near-term. The bold forecast suggests QCLS stock could more than 12x from here in 2026.

Shkreli’s latest call arrives only a day after he acknowledged being super wrong about Capricor Therapeutics Inc (NASDAQ: CAPR).

Versus the start of December, Q/C Technologies shares are now up well over 100%.

Why is Shkreli bullish on QCLS stock?

Martin Shkreli is unusually bullish on QCLS shares as he believes optical computing, rather than quantum computing, represents the true future of high-performance computing.

According to him, photonic technology could execute matrix multiplications at speeds far beyond current GPU capabilities, positioning Q/C Technologies as a potential leader in next-gen hardware.

In his post on X, Shkreli confirmed that he and his partner, who has also been invited to join the board, have taken a significant stake in the New York-headquartered firm.

Shkreli dubbed data from the firm’s Israeli partner “more impressive than current quantum stocks” and revealed plans to advise what he called “the next hardware lab for HPC.”

Shkreli was massively wrong on CAPR shares

Investors must still practice caution in playing Q/C Technologies stock at current levels, as Shkreli’s track record with such bold calls is checkered at best.

The former pharma executive had previously recommended short selling Capricor Therapeutics – arguing the firm’s HOPE-3 late-stage trial for deramiocel – its candidate treatment for Duchenne Muscular Dystrophy would fail.

But the biotech firm surprised the market with statistically significant positive results for that Phase 3 trial – triggering a more than 4x rally that left Shkreli’s short thesis in tatters.

The explosive rally even made Martin Shkreli publicly acknowledge that he made a “bad call” on CAPR stock that sits comfortably above the $25 level at the time of writing.

Why QCLS shares remain unattractive heading into 2026

Beyond Shkreli’s track record, there are several risks tied to QCLS shares that warrant caution in buying it at current levels.

For starters, the company has limited revenue streams while the commercialization of photonic computing is in its infancy.

Unlike established hyperscalers, Q/C Technologies lacks scale, recurring cash flow, and a diversified customer base. Plus, execution risks are high, with technological breakthroughs yet to be validated in mainstream enterprise settings.

Competition from quantum and GPU‑based solutions also remains fierce. So, investor enthusiasm could fade rather quickly if milestones are delayed.

Taken together with a more than 100% surge in QCLS stock in recent sessions, the company immediately starts to look more like a speculative bet than a sound long-term investment.

The post Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR appeared first on Invezz

Read the article at Invezz

In This News

Coins

$ 0.0757

+0.56%

Share:

In This News

Coins

$ 0.0757

+0.56%

Share:

Read More

Tesla stock trades in the green: is this the start of a December bounce?

Tesla stock trades in the green: is this the start of a December bounce?

Tesla stock (NASDAQ: TSLA) is trading on the right side of the tape Thursday, posting...
BBAI stock gains 12% on Thursday: is the Ask Sage acquisition finally paying off?

BBAI stock gains 12% on Thursday: is the Ask Sage acquisition finally paying off?

BigBear.ai (NYSE: BBAI stock) surged roughly 12% on Thursday, snapping a weeks-long c...

Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR


by Wajeeh Khan
for Invezz
Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR

Share:

martin shkreli qcls stock long idea bad call capr

Q/C Technologies In (NASDAQ: QCLS) soared another 60% on Thursday morning after former pharmaceutical executive Martin Shkreli touted the company as a “long idea”.

According to him, the photonic computing firm could be trading at $100 per share, and that too in the near-term. The bold forecast suggests QCLS stock could more than 12x from here in 2026.

Shkreli’s latest call arrives only a day after he acknowledged being super wrong about Capricor Therapeutics Inc (NASDAQ: CAPR).

Versus the start of December, Q/C Technologies shares are now up well over 100%.

Why is Shkreli bullish on QCLS stock?

Martin Shkreli is unusually bullish on QCLS shares as he believes optical computing, rather than quantum computing, represents the true future of high-performance computing.

According to him, photonic technology could execute matrix multiplications at speeds far beyond current GPU capabilities, positioning Q/C Technologies as a potential leader in next-gen hardware.

In his post on X, Shkreli confirmed that he and his partner, who has also been invited to join the board, have taken a significant stake in the New York-headquartered firm.

Shkreli dubbed data from the firm’s Israeli partner “more impressive than current quantum stocks” and revealed plans to advise what he called “the next hardware lab for HPC.”

Shkreli was massively wrong on CAPR shares

Investors must still practice caution in playing Q/C Technologies stock at current levels, as Shkreli’s track record with such bold calls is checkered at best.

The former pharma executive had previously recommended short selling Capricor Therapeutics – arguing the firm’s HOPE-3 late-stage trial for deramiocel – its candidate treatment for Duchenne Muscular Dystrophy would fail.

But the biotech firm surprised the market with statistically significant positive results for that Phase 3 trial – triggering a more than 4x rally that left Shkreli’s short thesis in tatters.

The explosive rally even made Martin Shkreli publicly acknowledge that he made a “bad call” on CAPR stock that sits comfortably above the $25 level at the time of writing.

Why QCLS shares remain unattractive heading into 2026

Beyond Shkreli’s track record, there are several risks tied to QCLS shares that warrant caution in buying it at current levels.

For starters, the company has limited revenue streams while the commercialization of photonic computing is in its infancy.

Unlike established hyperscalers, Q/C Technologies lacks scale, recurring cash flow, and a diversified customer base. Plus, execution risks are high, with technological breakthroughs yet to be validated in mainstream enterprise settings.

Competition from quantum and GPU‑based solutions also remains fierce. So, investor enthusiasm could fade rather quickly if milestones are delayed.

Taken together with a more than 100% surge in QCLS stock in recent sessions, the company immediately starts to look more like a speculative bet than a sound long-term investment.

The post Martin Shkreli touts QCLS stock as a long idea after a “bad call” on CAPR appeared first on Invezz

Read the article at Invezz

In This News

Coins

$ 0.0757

+0.56%

Share:

In This News

Coins

$ 0.0757

+0.56%

Share:

Read More

Tesla stock trades in the green: is this the start of a December bounce?

Tesla stock trades in the green: is this the start of a December bounce?

Tesla stock (NASDAQ: TSLA) is trading on the right side of the tape Thursday, posting...
BBAI stock gains 12% on Thursday: is the Ask Sage acquisition finally paying off?

BBAI stock gains 12% on Thursday: is the Ask Sage acquisition finally paying off?

BigBear.ai (NYSE: BBAI stock) surged roughly 12% on Thursday, snapping a weeks-long c...